Browse the corpus

Human T-cell lymphotropic viruses (HTLVs) are a family of human retroviruses with oncogenic potential and the ability to cause a spectrum of inflammatory and immunosuppressive diseases. Of the 4 identified types, including HTLV-1 through HTLV-4, HTLV-1 is the most clinically significant and best characterized. Although most infected individuals remain asymptomatic, a small percentage develop serious complications such as adult T-cell leukemia/lymphoma or HTLV-1–associated myelopathy/tropical spastic paraparesis. Endemic globally, HTLV-1 infection is increasingly recognized among intravenous drug users in the United States, underscoring its evolving epidemiologic relevance. This activity provides clinicians with an in-depth understanding of HTLV-1, including its epidemiology, transmission, clinical manifestations, and management strategies. Participants review current evidence on disease prevention and emerging therapeutic approaches, with an emphasis on the role of interprofessional collaboration in optimizing diagnosis, patient education, and long-term care for affected individuals. Objectives: Differentiate human T-cell lymphotropic virus-associated conditions. Screen at-risk populations, including those in endemic regions and individuals with relevant exposure histories, for early detection and intervention. Apply appropriate diagnostic testing, including serologic and molecular assays, to confirm infection. Communicate effectively with patients about the implications of disease, prevention, and long-term management. Access free multiple choice questions on this topic.

Human T-lymphotropic viruses (HTLVs) are a family of human retroviruses recognized as oncoviruses. These viruses are known for causing immunosuppressive and inflammatory diseases. Among them, HTLV-1 is the most clinically significant and was the first pathogen demonstrated to induce malignant disease. HTLV-1 was identified in 1980 from a cell line derived from a patient with cutaneous T-cell lymphoma.[1] The discovery of HTLV-1 marked the first identification of a human retrovirus, sparking further investigations into the relationship between hematological malignancy and retroviruses. Today, HTLV-1 is regarded as one of the most potent oncogenic agents in humans.[2] Although approximately 95% of infected individuals remain asymptomatic, about 5% may develop malignant, inflammatory, or opportunistic disease. Clinical manifestations include HTLV-1–associated myelopathy (HAM) and tropical spastic paraparesis (TSP). HTLV-2, identified from hairy T-cell leukemia cell lines in 1982, is associated with a phenotype presentation similar to HAM/TSP in a small percentage of affected individuals.[3][4] Unlike HTLV-1, however, HTLV-2 has not been clearly associated with malignancy. Similarly, HTLV-3 and HTLV-4 have not been shown to have causative relationships with malignancy.[5] HTLV-1 exhibits a strong oncogenic potential and carries a higher incidence of associated complications compared to other members of the HTLV family. The etiology, pathophysiology, evaluation, and management of HTLV-1 are fundamental to understanding its clinical significance.

HTLV-1 is an enveloped, single-stranded RNA retrovirus. The genomic organization of HTLV-1 is characteristic of the Retroviridae family, comprising 2 long terminal repeat (LTR) sequences, along with the group-specific core antigen (Gag), polymerase (Pol), and envelope (Env) genes. A distinguishing feature of HTLV-1 is the additional identifying pX region, which encodes several regulatory proteins, including the Tax protein. The Tax protein is strongly implicated in the pathophysiology of HTLV-1.[6] HTLV-1 infection occurs primarily and most efficiently via the transmission of infected lymphocytes, although free viral particles have been demonstrated to infect dendritic cells.[7] Once infected, CD4+ cells produce CCL22 (a CCR4 ligand), which attracts CCR4-expressing CD4+ cells to form what is termed the virological synapse.[8] This process potentiates preferential transmission of HTLV-1 within a CCR4+ CD4+ T-cell population. Although both HTLV-1 and HIV infect T cells, there are essential differences in their virology and pathophysiology.[9] This mode of cell-to-cell transmission is an example of one such difference and results in the very low viremia observed in HTLV-1 infection, in contrast to the high viral loads of HIV. After infection of T-cell lines, HTLV-1 replication is thought to occur mainly through clonal expansion, reducing the need for high replication rates.[10] This characteristic contributes to the virus's long latency, allowing it to remain dormant in lymphocytes for years before, in some cases, leading to oncogenic transformation and the development of HAM/TSP or adult T-cell leukemia. A second defining feature of HTLV-1 is its genetic stability, which is maintained by its replication strategy.[11] Following reverse transcription and integration into the host genome, replication occurs either through re-expression of the provirus or via host cell mitosis, whereby the provirus is duplicated with the genome. Because replication depends on host cell division rather than an independent viral polymerase, viral turnover is low while transcription fidelity remains high.[12] This produces a genetically stable product, sharply contrasting with the variability of HIV and conferring resistance to immune escape.[13]

A second defining feature of HTLV-1 is its genetic stability, which is maintained by its replication strategy.[11] Following reverse transcription and integration into the host genome, replication occurs either through re-expression of the provirus or via host cell mitosis, whereby the provirus is duplicated with the genome. Because replication depends on host cell division rather than an independent viral polymerase, viral turnover is low while transcription fidelity remains high.[12] This produces a genetically stable product, sharply contrasting with the variability of HIV and conferring resistance to immune escape.[13] HTLV-1 can regulate its own transcription and, therefore, transiently expresses gene products that contribute to evading host immune control.[14] Two regulatory proteins facilitate this process—Tax, which activates transcription, and Rex, which suppresses it.[15] The integration of the provirus and subsequent translation of viral products promote cellular proliferation and enhanced survival, thereby ensuring viral persistence. Unlike HIV infection, HTLV-1 does not induce cellular death; instead, T cells evade apoptosis and are prone to transformation.[16] HTLV-1 is structurally similar to simian T-lymphocytic virus. Both viruses share a common ancestor, with HTLV-1 emerging in humans through zoonotic exposure.[17][18] Documented cases have shown that HTLV-1 strains closely related to simian T-lymphocytic virus can be transmitted from nonhuman primates to human hunters.[19] HTLV-1 consists of multiple molecular subtypes, classified from A to G based on the coding and noncoding regions of the proviral genomes.[20] These subtypes are thought to have evolved from ancestral simian strains that coevolved with humans over thousands of years. This distribution of subtypes is geographically distinct. HTLV-1a is the most widespread, particularly across Africa and Japan, whereas HTLV-1c is found predominantly among Australo-Melanesian populations and may have originated from Southeast Asia.[21][22] Ongoing research is exploring the relationship between viral subtype and disease predisposition. For example, evidence suggests that subtype 1c may be more strongly associated with bronchial disease.[23]

HTLV-1 is estimated to infect 10 to 20 million people worldwide.[24] HTLV-1 is endemic in Japan, parts of Africa, central Australia, South America, and the Caribbean, though the actual number is difficult to estimate due to limited systematic serological testing. Although global endemics of HTLV-1 and HTLV-2 have long been recognized, an emerging epidemic has been noted among intravenous drug users across the United States.[25] Japan is traditionally recognized as the most endemic country for HTLV-1. Incidence rates have been documented at 3.8 per 100,000 person-years, with higher rates observed in women (6.9 per 100,000 person-years) compared to men (2.3 per 100,000 person-years).[24] In contrast, undercounting in central Australia has masked the true burden of disease. Serosurveys in geographically isolated indigenous communities have revealed prevalence rates as high as 50%.[26][27] Epidemiological patterns also show sex-based differences in disease expression. Men are more susceptible to adult T-cell leukemia/lymphoma (ATLL), whereas women are more frequently affected by HAM/TSP.[28] There are 3 major routes of HTLV-1 transmission—vertical transmission from mother to child via breastmilk (the most common route), sexual intercourse, and blood transfusions.[29] HTLV-1 has been isolated in breastmilk, and breastfed children are 4 times more likely to be infected than bottle-fed infants of infected mothers.[30] Breastfeeding duration is a major factor influencing the risk of transmission. Maternal antibodies transferred during pregnancy appear to provide partial protection for several months after birth. However, after 3 months of breastfeeding, the risk of transmission increases up to 3-fold despite the continued presence of maternal antibodies.[31][32] Short-term breastfeeding is associated with a lower risk, but practical factors, such as maternal-child bonding, limited access to formula, lack of storage facilities, and financial constraints, may prolong weaning, particularly in low-resource and remote communities. Bottle-fed infants remain at a significantly lower risk, though not entirely free from danger. The estimated risk of transmission rate is 0.6% at 1 year and 4.6% at 4 years.[33]

Breastfeeding duration is a major factor influencing the risk of transmission. Maternal antibodies transferred during pregnancy appear to provide partial protection for several months after birth. However, after 3 months of breastfeeding, the risk of transmission increases up to 3-fold despite the continued presence of maternal antibodies.[31][32] Short-term breastfeeding is associated with a lower risk, but practical factors, such as maternal-child bonding, limited access to formula, lack of storage facilities, and financial constraints, may prolong weaning, particularly in low-resource and remote communities. Bottle-fed infants remain at a significantly lower risk, though not entirely free from danger. The estimated risk of transmission rate is 0.6% at 1 year and 4.6% at 4 years.[33] Sexual transmission accounts for a significant proportion of the HTLV-1 burden in Central Australia. Prevalence is lower among children than in older age groups, suggesting that sexual exposure substantially increases the risk of acquisition from adolescence through adulthood.[27] Transmission is typically more efficient from males to females, with an estimated rate of 5:1. This imbalance is reflected in global data, where seroconversion rates are consistently higher among females than males.[34][35] However, studies in Australia show a disordant pattern, with higher prevalence reported among men than women, an observation that remains unexplained.[27] HAM/TSP is associated with sexual transmission and blood transfusion.[36] Vertical and sexual transmission are the most common routes of infection.[37] Risk factors for HAM/TSP include young age at first sexual encounter and having more than 5 lifetime sexual partners.[38] These risk factors are not identified in ATLL, which is more strongly associated with vertical transmission of HTLV-1. Transfusion of infected blood carries a high risk of rapid seroconversion.[39] This risk has been significantly reduced in countries that routinely screen blood products, such as the United States, Canada, the United Kingdom, Australia, New Zealand, Japan, and Brazil. In the United States, organ donations are also screened for both HTLV-1 and HTLV-2.

Transfusion of infected blood carries a high risk of rapid seroconversion.[39] This risk has been significantly reduced in countries that routinely screen blood products, such as the United States, Canada, the United Kingdom, Australia, New Zealand, Japan, and Brazil. In the United States, organ donations are also screened for both HTLV-1 and HTLV-2. Although data on transfusion-related transmission remain limited, small studies suggest that the risk of infection is substantial when a seronegative recipient receives blood from a seropositive donor. In a study involving 10 patients, 7 seroconverted within 4.5 years, and 4 subsequently developed HAM/TSP.[40] The risk of occupational HTLV-1 exposure among healthcare workers from needlestick injuries has not been clearly quantified but is generally considered low. To date, no postexposure prophylaxis has been established or validated for HTLV-1.

HTLV-1 is commonly associated with 2 distinct diseases—ATLL, occurring in approximately 4% of infected individuals, and HAM/TSP, affecting approximately 2%.[28] A well-recognized gender difference exists, with men more susceptible to ATLL, whereas women are more frequently affected by HAM/TSP.[41] These conditions are associated with various transmission routes. ATLL is primarily related to vertical transmission, whereas HAM/TSP is more closely linked to blood transfusion. Because these transmission routes typically occur at different ages, the age of acquisition likely plays a crucial role in determining disease outcome. No significant differences in HTLV-1 strains have been identified, suggesting that a combination of cofactors and host immune responses determines clinical manifestations. Viral gene products interact with host transcription factors to mediate cellular transformation and, therefore, oncogenesis. Among these, Tax is the principal viral protein responsible for disruption via several routes. Tax upregulates T-cell survival pathways through interleukin (IL)-2 (IL-2) and IL-15 signaling and inhibits apoptosis by stimulating Bcl-XL, which prevents caspase activation. At the same time, Tax suppresses cell cycle control and DNA repair. Intracellularly, NF-κB activation drives inflammation, whereas HTLV-1 has also been shown to induce class-switching of T cells toward a T-helper 1 cell profile, further enhancing proinflammatory responses.[42] Additional mechanisms include high circulating levels of vascular endothelial growth factor, which promotes angiogenesis.[43] Both HTLV-1 and HTLV-2 have demonstrated the ability to transform human lymphocytes into self-sustaining populations in vitro. HTLV-1 infection elicits a humoral immune response, characterized by antibodies directed against the viral Gag, Env, and Tax proteins. The cellular response is mediated primarily by HTLV-specific cytotoxic lymphocytes, which recognize epitopes derived from the Tax protein. These cytotoxic cells are present in high numbers among asymptomatic carriers, suggesting a key role in controlling HTLV-1 replication and disease progression.[44]

HTLV-1 infection elicits a humoral immune response, characterized by antibodies directed against the viral Gag, Env, and Tax proteins. The cellular response is mediated primarily by HTLV-specific cytotoxic lymphocytes, which recognize epitopes derived from the Tax protein. These cytotoxic cells are present in high numbers among asymptomatic carriers, suggesting a key role in controlling HTLV-1 replication and disease progression.[44] The interaction between the host immune response and HTLV-1–encoded genes has been shown to facilitate an immunosuppressive environment. During acute infection, an IL-10-dominant cytokine profile emerges, supporting T-cell activity. Persistent viral proliferation contributes to CD8 T-cell exhaustion, leading to impaired virus-specific suppression—an important mechanism underlying both chronic viral-mediated immunosuppression and oncogenesis.[45] In addition, inflammatory cascades triggered by CD4 T-cell activation are thought to play a central role in the pathogenesis of HAM/TSP.[46] This chronic immune activation contributes to progressive spinal cord inflammation and demyelination, ultimately leading to the characteristic motor deficits of the disease.

Acute HTLV-1 infections are rarely identified or diagnosed because the initial infection is often asymptomatic.[47] Suspected or confirmed cases may prompt an investigation into potential transmission routes, such as a recent blood transfusion or breastfeeding from a mother in an endemic area. No specific treatment is indicated for acute HTLV-1 infection. However, lifestyle counseling is essential, including guidance on breastfeeding practices, safe sexual activity, and vigilance for evolving clinical symptoms. ATLL is defined as a neoplastic clonal expansion of CD4+ T cells infected with HTLV-1. The lifetime risk of developing ATLL among individuals infected with HTLV-1 is estimated to be 4% to 7%, with malignant transformation typically occurring after a latency period of up to 30 years.[48][49] The presenting features of ATLL often include generalized lymphadenopathy, cutaneous lymphadenopathy, cutaneous lesions, hepatosplenomegaly, and immunosuppression, which may be evidenced by the development of opportunistic infections. Paraneoplastic hypercalcemia is typically present at diagnosis and may be caused by tumor necrosis factor-β or parathyroid hormone-related protein. Accelerated bone turnover and lytic bone lesions are also frequent findings.[50] Patients in the early stages of disease may lack typical manifestations, and in some cases, presentation is delayed until the onset of fulminant disease.[51] Classifications of ATLL The wide variability in clinical presentation and disease course of ATLL has led to its subclassification into 4 categories—acute, characterized by aggressive disease with leukemic features; lymphomatous, marked by predominant nodal involvement without circulating malignant cells; chronic, associated with leukemic features but a more indolent course; and smoldering, defined by minimal symptoms and slow progression.[52] This classification provides important prognostic value and guides therapeutic decision-making.

The wide variability in clinical presentation and disease course of ATLL has led to its subclassification into 4 categories—acute, characterized by aggressive disease with leukemic features; lymphomatous, marked by predominant nodal involvement without circulating malignant cells; chronic, associated with leukemic features but a more indolent course; and smoldering, defined by minimal symptoms and slow progression.[52] This classification provides important prognostic value and guides therapeutic decision-making. Acute: The acute type is the most common presentation of ATLL, accounting for approximately 55% of cases, and is associated with the poorest prognosis, with a median survival of only 6 months from diagnosis. Clinical features include skin lesions, bone pain caused by hypercalcemia, and lytic bone lesions, as well as pulmonary symptoms with infiltrates visible on chest imaging. Pulmonary features may result from primary disease or from opportunistic infections, which are present in 30% of patients at the time of diagnosis. Opportunistic organisms include Pneumocystis jirovecii (causing pneumonia, often observed in patients with AIDS), Cryptococcus neoformans (leading to occult meningitis),[53] Herpes zoster, and Strongyloides stercoralis infestation, which can cause life-threatening hyperinfection.[46][54] Lymphomatous: The lymphomatous form accounts for 20% of ATLL cases. This form is characterized by massive lymphadenopathy and splenomegaly, typically without tumor cells.[55] Skin lesions may also occur, and hypercalcemia is common at presentation, often leading to complications, such as renal impairment and neuropsychiatric disturbance. Chronic: The chronic subtype accounts for approximately 20% of all ATLL cases and has a more indolent course than the acute and lymphomatous forms. Median survival is around 2 years.[52] Smoldering: The smoldering subtype is the rarest form of ATLL, accounting for only 5% of the disease burden. Cutaneous features are common but generally milder than those observed in the acute subtype. Respiratory or gastrointestinal symptoms are typically absent. Diagnostic criteria include involvement of fewer than 5% of peripheral CD4+ T cells.[56] Median survival without treatment is 3 years. HAM/TSP

Smoldering: The smoldering subtype is the rarest form of ATLL, accounting for only 5% of the disease burden. Cutaneous features are common but generally milder than those observed in the acute subtype. Respiratory or gastrointestinal symptoms are typically absent. Diagnostic criteria include involvement of fewer than 5% of peripheral CD4+ T cells.[56] Median survival without treatment is 3 years. HAM/TSP HTLV-1–associated myelopathy/TSP is a chronic myelopathy that develops and progresses gradually over time. In some cases, however, more rapid deterioration has been observed, which is thought to correlate with high viral loads, although no definitive threshold for increased risk has been established.[57] HAM/TSP occurs in approximately 0.25% to 3% of individuals living with HTLV-1.[49] The typical presentation of HAM/TSP is a slowly progressive paraparesis with associated spasticity. The earliest physical signs typically appear in the lower limbs, but involvement of the upper limbs may follow. Weakness tends to be more pronounced in the proximal areas.[58] Widespread pyramidal signs are almost always observed. Sensory signs are typically subtle, with impaired vibration sense indicating the earliest defect; however, a clear sensory level is uncommon. The thoracic spinal cord is the site most commonly affected by viral-mediated inflammation. Many patients also experience severe thoracolumbar back pain, which is among the most debilitating features of the disease and is often difficult to control. Neuropathic agents, in combination with standard analgesics, are typically required for management.[59] Autonomic dysfunction is a well-recognized feature of HAM/TSP. Patients may experience orthostatic hypotension and disturbances of sweating, including hyperhidrosis or hypohidrosis, which can significantly impair quality of life.[60] Bladder dysfunction is often an early sign, initially presenting as urgency and later progressing to urinary incontinence. Cognitive function is classically intact. The clinical course of HAM/TSP is highly variable. Some patients experience rapid progression, becoming a wheelchair user within a short period, whereas others maintain minimal weakness even decades after diagnosis. At present, there are no reliable methods to predict disease progression.[61] Additional Disease Associations

The clinical course of HAM/TSP is highly variable. Some patients experience rapid progression, becoming a wheelchair user within a short period, whereas others maintain minimal weakness even decades after diagnosis. At present, there are no reliable methods to predict disease progression.[61] Additional Disease Associations Beyond ATLL and HAM/TSP, HTLV-1 has been implicated in a broad spectrum of additional disease associations across multiple organ systems. Reported conditions include neurological syndromes, dermatologic and ophthalmologic disorders, and rheumatologic and pulmonary manifestations, reflecting the virus's broad pathogenic potential. Neurologic manifestations: HTLV-1 is linked to a range of other neurological diseases, including subacute meningitis, encephalitis, amyotrophic lateral sclerosis syndromes, and conus medullaris syndrome.[58] These associations are less well established than the 2 primary HLTV-1-related diseases, and the underlying mechanisms remain incompletely understood. Dermatologic manifestations: HTLV-1 is associated with infective dermatitis, typically affecting the face, scalp, and flexures of infected children. Clinically, it is characterized by an eczematous rash that is frequently secondarily infected with organisms such as Staphylococci and Streptococci species.[62] The condition typically improves during adolescence and is rare in adults. HTLV-1 has been linked to seborrheic dermatitis and dermatophytosis.[46] Ophthalmologic manifestations: HTLV-1–associated uveitis presents with floaters and blurred vision, frequently affecting both eyes, and is more common in patients younger than 50. On examination, the anterior chamber appears cloudy with cells, and retinal involvement may also be observed, including hemorrhages and exudates. Although patients respond well to topical steroid therapy, relapses are common once treatment is tapered, necessitating long-term management and increasing the risk of steroid-induced glaucoma.[63]

Ophthalmologic manifestations: HTLV-1–associated uveitis presents with floaters and blurred vision, frequently affecting both eyes, and is more common in patients younger than 50. On examination, the anterior chamber appears cloudy with cells, and retinal involvement may also be observed, including hemorrhages and exudates. Although patients respond well to topical steroid therapy, relapses are common once treatment is tapered, necessitating long-term management and increasing the risk of steroid-induced glaucoma.[63] Rheumatologic manifestations: A variety of autoimmune conditions are observed with increased frequency in HTLV-1–infected patients, including polymyositis, fibromyalgia, Sjögren syndrome, and Raynaud disease.[49][46] These associations are believed to result from chronic immune activation and dysregulation driven by persistent viral infection. The overlap between HTLV-1–related immune phenomena and classic autoimmune disease highlights the complex interplay between viral persistence, host response, and systemic inflammation. Pulmonary manifestations: Bronchiolar disease occurs with a significantly higher incidence in individuals with HTLV-1 compared to the general population. An extensive prospective study in Australia found that 60% of patients hospitalized with bronchiectasis were HTLV-1–positive, compared to a background prevalence of 10%.[64] Similarly, a study in the United Kingdom found that 3% of patients infected with HTLV-1 had computed tomography evidence of bronchiectasis, in contrast to a prevalence of 0.1% in the general population. The underlying mechanism for this association remains unclear.[65] Furthermore, HTLV-1 infection has been linked to asthma and an increased risk of respiratory infections, including community-acquired pneumonia and tuberculosis. However, much of the supporting evidence comes from small or low-quality observational studies, and these associations remain less defined.[46] Malignancy manifestations: Malignancies have also been linked to HTLV-1 infection. A meta-analysis demonstrated positive associations with liver cancer, lymphomas other than ATLL, and cervical cancer. Notably, HTLV-1 infection was associated with a lower risk of gastric cancer.[46]

For HTLV-1, the definitive diagnosis relies on serological testing. Enzyme-linked immunosorbent assay is often employed as a screening tool, followed by Western blot as a confirmatory study to identify antibodies against the viral Gag and Env proteins. However, depending on the validity of the Western blot used and laboratory standards, indeterminate results may occur in 5% to 65% of cases.[66] In these cases, molecular testing can be used to confirm HTLV-1 infection. Polymerase chain reaction (PCR) offers the advantage of quantifying proviral load and differentiating between HTLV-1 and HTLV-2.[67] This method is beneficial for assessing pregnant individuals, as proviral load can help estimate the risk of vertical transmission through breastfeeding. However, PCR requires specialized primers targeting the HTLV Pol gene, and mutations or deletions in this region can complicate standardization and the interpretation of results. As a result, PCR testing is typically conducted in reference laboratories equipped with sufficient reagents and primers to ensure accurate measurement of proviral loads. The clinical interpretation of proviral load remains uncertain, as no threshold has been identified to reliably predict disease risk or clinical outcomes. The primary value of proviral load lies in assessing the risk of mother-to-child transmission, as higher loads are strongly predictive of vertical transmission.[30] Proviral load does not vary significantly during pregnancy, but it can increase postpartum, particularly when breastfeeding.[68][69] Therefore, accurate testing and comprehensive counseling are essential when treating expectant mothers, especially given the absence of curative HTLV-1. Further diagnostic tools are under development, including lateral flow assays. Currently, these tests are either awaiting validation or are primarily used for screening purposes rather than diagnosis.[70][71] In ATLL, patients may present with a markedly elevated white blood cell count and persistent lymphocytosis, depending on the stage of the disease.[72] Diagnostic evaluation requires examination of peripheral blood cells and bone marrow, which also aids in subclassification.

Further diagnostic tools are under development, including lateral flow assays. Currently, these tests are either awaiting validation or are primarily used for screening purposes rather than diagnosis.[70][71] In ATLL, patients may present with a markedly elevated white blood cell count and persistent lymphocytosis, depending on the stage of the disease.[72] Diagnostic evaluation requires examination of peripheral blood cells and bone marrow, which also aids in subclassification. Pathognomonic morphological features of leukemic ATLL lymphocytes include dense chromatin with lobulated, cloverleaf-shaped nuclei, often referred to as flower cells.[73] Scattered blast cells may also be visible on blood film, whereas bone marrow examination typically demonstrates patchy infiltrates. Histological assessment of lymphoid tissue is essential when lymphomatous disease is suspected. Involved lymph nodes show markedly distorted architecture with pleomorphic cells that can resemble Reed-Sternberg cells, occasionally leading to diagnostic confusion with Hodgkin lymphoma.[72] Similarly, biopsy of cutaneous lesions may reveal findings similar to those of mycosis fungoides, a form of cutaneous T-cell lymphoma. Several markers have been identified as predictors of disease progression in ATLL, including serum CD25, thymidine kinase, and neuron-specific enolase, though these tests are rarely available outside specialist centers.[74] However, none of these markers have been standardized for routine clinical use, and their utility remains largely confined to research or specialized diagnostic settings. The World Health Organisation established diagnostic criteria for HAM/TSP in 1988, incorporating clinical, imaging, and laboratory findings. In current practice, however, newer techniques, such as PCR-based quantification of HTLV-1 viral load in cerebrospinal fluid (CSF), are typically incorporated into the diagnostic process.[75] Magnetic resonance neuroimaging may reveal discrete white matter lesions or spinal cord atrophy, whereas CSF analysis typically identifies mild leucocytosis, moderately elevated protein levels, and detectable anti-HTLV-1 antibodies.

The World Health Organisation established diagnostic criteria for HAM/TSP in 1988, incorporating clinical, imaging, and laboratory findings. In current practice, however, newer techniques, such as PCR-based quantification of HTLV-1 viral load in cerebrospinal fluid (CSF), are typically incorporated into the diagnostic process.[75] Magnetic resonance neuroimaging may reveal discrete white matter lesions or spinal cord atrophy, whereas CSF analysis typically identifies mild leucocytosis, moderately elevated protein levels, and detectable anti-HTLV-1 antibodies. Recognizing the potential for confusion surrounding HTLV nomenclature is important. The term HTLV-3 was initially assigned to the virus now known as HIV before it was reclassified as a separate entity. Similarly, HTLV-4 was previously used synonymously with HIV-2. This overlap in terminology has contributed to clinical misunderstandings, with studies showing that more than 90% of diagnostic HTLV test requests were actually intended for HIV testing.[76]

The management of HTLV-1 infection remains challenging, as no curative therapy currently exists for the virus itself. Treatment strategies focus on controlling associated diseases such as ATLL and HAM/TSP, alleviating symptoms, and reducing the risk of transmission. Currently, no approved treatment exists for HTLV. However, emerging evidence suggests that certain antiretroviral agents used in HIV therapy can be repurposed for HTLV. Laboratory studies have shown that tenofovir disoproxil is highly potent against HTLV, inhibiting the transmission of the virus.[47][77] Similar findings have been observed for dolutegravir, which targets the conserved integrase found in HTLV.[78] If confirmed in human studies, these agents could represent important advances in preventing mother-to-child HTLV transmission. ATLL Management Various combination chemotherapy regimens have been compared to highly active antiretroviral therapy protocols to improve morbidity and mortality in patients with ATLL. Limited evidence suggests that highly active antiretroviral therapy, including zidovudine and interferon-α, may be beneficial in lymphomatous ATLL, whereas multiagent chemotherapy appears more effective in acute, aggressive leukemic ATLL. Switching between these strategies is recommended for nonresponders.[43] Intensive chemotherapy followed by allogenic hematopoietic stem-cell transplantation has shown promise in younger patients with aggressive ATLL. However, its broader use is limited, as many patients are ineligible due to age, with a median age at diagnosis of 68.[24] Long-term maintenance combination chemotherapy with vincristine/methotrexate, prednisolone, etoposide/cyclophosphamide (OPEC/MPEC) has been shown to improve survival and quality of life in older patients with ATLL.[79] HAM/TSP Management Treatment options for HAP/TSP remain limited, and most therapies provide only modest benefit. The mainstay of management is symptomatic care. Corticosteroids have been widely used, with limited evidence suggesting a moderate benefit in slowing disease progression. Japanese centers have reported encouraging results with mogamulizumab, a monoclonal antibody that targets CCR4, noting a decrease in spasticity and an improvement in motor function.[80]

Treatment options for HAP/TSP remain limited, and most therapies provide only modest benefit. The mainstay of management is symptomatic care. Corticosteroids have been widely used, with limited evidence suggesting a moderate benefit in slowing disease progression. Japanese centers have reported encouraging results with mogamulizumab, a monoclonal antibody that targets CCR4, noting a decrease in spasticity and an improvement in motor function.[80] Antiviral therapies outside of research settings have been disappointing, failing to modify disease progression. For example, capsid inhibitors developed for HIV cannot be repurposed for HTLV despite both being retroviruses, as differences in viral envelope structure prevent effective drug targeting. Vaccination Currently, no vaccine exists for HTLV-1; however, several viral characteristics suggest that vaccine development may be feasible. These characteristics include the virus's low antigenic variability and evidence that natural immunity can develop in humans. Animal studies using envelope antigens have also produced encouraging results.[25] The CCR4 receptor has been identified as a potential therapeutic target due to its central role in viral transmission and the host immune response. Ongoing research is exploring innovative approaches, including messenger RNA platforms, exosome-based delivery systems, and molecular clamp technologies, with emerging animal and laboratory studies yielding promising results.[81][82][83]

Distinguishing HTLV-1–related diseases from other hematologic and neurologic conditions can be difficult, as their clinical, histologic, and even immunophenotypic features often overlap. The careful integration of clinical history, laboratory testing, and molecular diagnostics is therefore essential to achieve an accurate diagnosis. For ATLL, the differential centers around other T-cell malignancies, and deciphering these can be challenging. ATLL can mimic cutaneous T-cell lymphoma, as cutaneous features are similar both macroscopically and histologically, and even immunohistochemical profiles may be indistinguishable in some cases. The lymphomatous subtype can produce lymphadenopathy that morphologically resembles Hodgkin disease, with apparent Reed-Sternberg cells.[84] Examination of peripheral blood cells in asymptomatic patients with HTLV-1–infected individuals may reveal the characteristic flower cells of ATLL. Differentiating smoldering ATLL from asymptomatic HTLV-1 carriers without malignancy is particularly difficult, and PCR analysis to identify a malignant T-cell clone can aid in confirmation. The principal differential diagnosis for HAM/TSP is multiple sclerosis, particularly the primary progressive form in patients from HTLV-1–endemic regions. Identifying the presence of HTLV-1 in CSF is essential for diagnosis. Other neurological diseases, including amyotrophic lateral sclerosis and conus medullaris syndrome, have also been associated with HTLV-1, but establishing causality in patients with concurrent HTLV-1 and neurological disease remains a significant challenge.

Acute HTLV-1 infection is typically undetected and often occurs early in life through vertical transmission. The prolonged and variable latency between infection and disease onset suggests that viral presence alone is insufficient for pathogenesis, with additional, poorly understood host or environmental factors likely involved. Prognostic understanding, therefore, remains incomplete. A meta-analysis demonstrated a 57% increased relative risk of all-cause mortality among individuals living with HTLV-1 infection compared to those living without, although the contribution of proviral load and other cofactors remains unclear.[46] These findings underscore the importance of prevention and transmission control in the absence of curative therapy. ATLL carries a poor prognosis due to intrinsic chemoresistance and profound immunosuppression.[43] Outcomes depend on disease subtype, with the acute form associated with the shortest survival. In a US cohort of 195 patients followed for 16 years, the median survival was 4 months for acute ATLL (n=80), 10 months for lymphomatous ATLL (n=96), and 72 months for chronic or smoldering ATLL (n=12). Although survival appears more favorable in the indolent subtypes, these represent only 6% of the total study patients.[56] The clinical course of HAM/TSP is highly variable, with few reliable predictors of progression beyond viral loads.[85] Most patients experience a gradual neurologic decline, whereas a minority progress to wheelchair dependence. In contrast, some individuals maintain near-normal function for decades, exhibiting only mild motor impairment.[61]

HTLV-1 is typically asymptomatic during the acute phase but leads to significant morbidity and mortality in approximately 5% of affected individuals through conditions including ATLL and HAM/TSP. These conditions generally develop years or decades after initial infection, contributing to delayed diagnosis and management. Although ATLL and HAM/TSP cause significant morbidity, the ability to predict disease onset, progression, and optimal treatment remains limited. Additional conditions associated with HTLV-1, including autoimmune, bronchial, and malignant manifestations, further contribute to long-term morbidity and impaired quality of life.

Patient awareness of HTLV-1, including knowledge of transmission routes and infection risk, remains limited even in populations with high prevalence.[86] Vulnerable groups, such as sex workers and people who inject drugs, are at increased risk of infection and often face significant barriers to healthcare access. There is a substantial need for public education addressing both vertical transmission through breastfeeding and horizontal transmission through sexual intercourse and needle-sharing.[87] Regulatory policies have demonstrated value in reducing the transmission of HTLV-1 in endemic regions. Japan implemented HTLV-1 antibody screening in blood donations in 1986 and issued national recommendations advising women living with HTLV to avoid breastfeeding.[88] Since then, Japan has expanded towards nationwide screening of pregnant women and recommends exclusive formula feeding over short-term breastfeeding as the preferred preventive strategy.[89] Recognizing HTLV-1 as a sexually transmitted infection is also critical for improving provider awareness and encouraging consistent use of barrier methods to reduce transmission. In high-prevalence settings, carefully designed education programs and shared decision-making between healthcare providers and patients are essential, particularly when counseling on testing, breastfeeding practices, and prevention strategies at the primary care level. Strengthening provider training and community engagement can foster earlier detection, reduce stigma, and promote informed, culturally sensitive approaches to HTLV-1 prevention and care.

Key facts to keep in mind about HTLV-1 include the following: Retrovirus belonging to the Retroviridae family, genus Deltaretrovirus Enveloped, single-stranded, positive-sense RNA virus Transmission: Sexual contact, breastfeeding (vertical), blood transfusion, and needle sharing Endemic regions: Japan, the Caribbean, parts of Africa, Central/South America, and Australia Infects primarily CD4+ T lymphocytes Associated diseases: ATLL HAM/TSP Long latency period between infection and disease onset (years to decades) Pathogenesis involves the Tax protein (promotes cell proliferation and inhibits apoptosis) Diagnosis: Enzyme-linked immunosorbent assay screening → Western blot confirmation → PCR for proviral DNA No curative therapy; management is supportive and disease-specific Prevention: Screen blood products, avoid breastfeeding if infected, safe sex, and needle hygiene Not the same as HIV (different envelope, slower progression, and low viremia)

Effective management of HTLV-1 requires coordinated, interprofessional collaboration to optimize patient outcomes and safety. Clinicians and advanced practitioners are responsible for diagnosis, counseling, and long-term monitoring. In contrast, nurses play a key role in patient education, psychosocial support, and adherence to infection prevention strategies. Pharmacists contribute to ensuring the safe and evidence-based use of antivirals, immunomodulators, and symptomatic therapies, as well as monitoring for adverse effects or interactions. Public healthcare professionals and social workers play a crucial role in community education, risk reduction, and addressing the social determinants of health. Ethical responsibilities include maintaining confidentiality, reducing stigma, and supporting informed decision-making, particularly regarding testing, breastfeeding, and reproductive choices. Regular interprofessional communication through shared care plans, multidisciplinary meetings, and culturally sensitive counseling enhances care coordination, improves early recognition of complications, and strengthens patient trust and engagement. Collectively, these strategies advance patient-centered care and improve long-term outcomes for individuals living with HTLV-1.